Science News & Science Current Events
 
Email a Friend Send to a friend
Printer Friendly Print HIV persists in the gut despite long-term HIV therapy

HIV persists in the gut despite long-term HIV therapy

February 14, 2008

Second study finds that B-cell abnormalities also persist

Even with effective anti-HIV therapies, doctors still have not been able to eradicate the virus from infected individuals who are receiving such treatments, largely because of the persistence of HIV in hideouts known as viral reservoirs. One important reservoir is the gut, where HIV causes much of its damage due to the large number of HIV target cells that reside there. These cells, known as CD4+ T cells, are largely contained in lymph nodes and patches of lymphocytes that collectively are called gut-associated lymphoid tissue, or GALT.




Because of the importance of the gut to HIV disease, scientists hoped that long-term treatment with antiretroviral drugs could eradicate HIV from the GALT. A new NIAID study, published online by The Journal of Infectious Diseases, has found that this goal seems unlikely with current antiretroviral drugs.

Tae-Wook Chun, Ph.D., of the NIAID Laboratory of Immunoregulation (LIR), Anthony S. Fauci, M.D., LIR chief and NIAID director, and their colleagues intensively studied eight patients receiving effective antiretroviral therapy for up to 9.9 years. In each of these of these individuals, therapy had consistently kept their blood levels of HIV at undetectable levels. Sensitive tests, however, detected the persistence of HIV as well as lowered CD4+ T cell levels in the GALT that did not completely rebound in response to therapy. Levels of virus were higher in the GALT than in immune cells in the blood, where HIV also was consistently found. In addition, the scientists found evidence of cross infection between the GALT and the lymphocytes in the blood, suggesting that one reason the virus persists in the blood is because of ongoing cycles of replication in the GALT. The authors conclude that any possibility of further lowering or eliminating viral reservoirs likely will require more powerful drug regimens to stop the low levels of ongoing viral replication originating in the GALT. The development of such regimens is an important goal of NIAID-supported research.

A second study from the Fauci laboratory, conducted by Susan Moir, Ph.D., and her colleagues and also published online by The Journal of Infectious Diseases provides additional insights into the effects of antiretroviral therapy on the HIV disease process.

In most HIV-infected individuals, the virus replicates at high levels and CD4+ T-cell numbers decline. These two factors also strongly affect B cells, the cells of the immune system that make antibodies and help protect against infection. Dr. Moir and her colleagues demonstrated that prior to treatment with antiretroviral therapy, B-cell numbers in the blood of HIV-infected individuals who have been infected for several years are low, and the B cells also include several dysfunctional subsets. After one year of effective treatment with antiretroviral therapy, B-cell numbers returned to normal, and several of the dysfunctional subsets also normalized. However, those B-cells that provide long-term protection against infection--so-called memory B cells--did not return to normal levels. Dr. Moir notes that these findings strengthen the notion that while antiretroviral therapy improves many aspects of immune function in HIV-infected individuals, important deficiencies remain, especially in individuals who wait several years before initiating therapy. More studies are needed to determine whether early initiation of antiretroviral therapy helps restore the immune system more completely.

NIH/National Institute of Allergy and Infectious Diseases



Related Antiretroviral Therapy Current Events and Antiretroviral Therapy News Articles Antiretroviral Therapy Current Events and Antiretroviral Therapy News RSS Antiretroviral Therapy Current Events and Antiretroviral Therapy News RSS
Study examines cost-effectiveness of HIV monitoring strategy in countries with limited resources
In a computer-based model evaluating the benefits and costs of three types of HIV disease monitoring strategies, early initiation of antiretroviral therapy and monitoring using the CD4 count, a measure of immune system function, instead of based on symptoms appear to provide health benefits in low- and middle-income countries.

ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells.

Adherence to antiretroviral therapy high in children in low income countries
Researchers from the Indiana University School of Medicine, the Regenstrief Institute and Moi University School of Medicine are the first to report that adherence to antiretroviral therapy (ART) to fight human immunodeficiency virus (HIV) in children who live in low income countries is as high as or higher than adherence by children living in high income countries.

U of M study shows why treatment isn't effective for HIV
University of Minnesota researchers have answered a key question as to why antiretroviral therapy isn't effective in restoring immunity in HIV-infected patients.

Study highlights risky behavior, lack of care among HIV-infected crack users
Doctors who treat HIV-infected crack users refer to them as "the forgotten population." A study being presented at this week's International AIDS Conference in Mexico City reveals that these patients frequently lack outpatient health care, do not receive life-saving antiretroviral therapy and continue to engage in risky sexual behavior that likely contributes to HIV transmission.

Long-term HIV treatment may reduce risk for atherosclerosis
Antiretroviral drugs for HIV do not increase the risk for coronary atherosclerosis, a central risk factor for heart disease, according to a study led by the University of Pittsburgh Graduate School of Public Health to be published in the Aug. 8 issue of the journal AIDS and available online today.

Certain HIV treatment less effective when used with anti-TB therapy
Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy.

International panel updates treatment guidelines for HIV infection
An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

Growth hormone treatment for HIV patients improves abdominal fat, but worsens glucose level
For human immunodeficiency virus (HIV)-infected patients with treatment-related abdominal obesity and growth hormone deficiency, receiving low-dose growth hormone resulted in improvement in fat and blood pressure measurements but worsened glucose levels.

Highly active antiretroviral therapy of similar benefit for HIV-infected injection drug users
Contrary to the belief that HIV-infected injection drug users (IDUs) receive less benefit from highly active antiretroviral therapy (HAART), new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART.
More Antiretroviral Therapy Current Events and Antiretroviral Therapy News Articles


Antiretroviral Therapy

No consensus on HAART's threat to the heart. (Study of 22,468 HIV Patients).(highly active antiretroviral therapy): An article from: Family Practice News
by Diana Mahoney

This digital document is an article from Family Practice News, published by International Medical News Group on May 1, 2003. The length of the article is 854 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Neurocognitive impairment risk no longer age related in HAART era.(highly active antiretroviral therapy): An article from: Internal Medicine News
by Sherry Boschert

This digital document is an article from Internal Medicine News, published by International Medical News Group on June 1, 2004. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand (1).: An article from: Emerging Infectious Diseases
by Somsak Akksilp, Opart Karnkawinpong, Wanpen Wattanaamornkiat, Daranee Viriyakitja, Patama Monkongdee, Walya Sitti, Dhanida Rienthong, Taweesap Siraprapasiri, Charles D. Wells, Jordan W. Tappero, Jay K. Varma

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on July 1, 2007. The length of the article is 5879 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Racial disparities persist in HIV care, especially HAART.(Infectious Diseases)(Highly active antiretroviral therapy): An article from: Internal Medicine News

This digital document is an article from Internal Medicine News, published by Thomson Gale on July 1, 2005. The length of the article is 527 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Racial...

Watch out for immune reconstitution disease in patients receiving HAART. (Usually Easily Treated).(highly active antiretroviral therapy): An article from: Internal Medicine News
by Robert Finn

This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2003. The length of the article is 426 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...



Potency and vulnerability: Troubled 'selves' in the context of antiretroviral therapy [An article from: Social Science & Medicine]
by A. Persson, C. Newman

This digital document is a journal article from Social Science & Medicine, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: The concepts of health and self have become intimately entangled in contemporary western society. Health is figured as a...

Sexual desire and practice among people living with HIV and using combination anti-retroviral therapies.: An article from: The Canadian Journal of Human Sexuality
by Eleanor Maticka-Tyndale, Barry D. Adam, Jeffrey Cohen

This digital document is an article from The Canadian Journal of Human Sexuality, published by SIECCAN, The Sex Information and Education Council of Canada on March 22, 2002. The length of the article is 4681 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase....

'Bumper crop' of new antiretroviral therapies shows promise for resistant HIV. (Overcoming Resistance Trend).: An article from: Internal Medicine News
by Diana Mahoney

This digital document is an article from Internal Medicine News, published by International Medical News Group on May 1, 2003. The length of the article is 899 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Antiretroviral Patients May Not Need CMV Therapy if CD4 Counts Are Adequate.(Brief Article): An article from: Family Practice News
by Steve Mitchell

This digital document is an article from Family Practice News, published by International Medical News Group on May 1, 2001. The length of the article is 451 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com